Immunosuppressive strategies with rituximab are increasing in patients with acquired thrombotic thrombocytopenic purpura (TTP) that is refractory/relapsing after standard treatment.1–3 Rituximab can effectively kill ADAMTS13-specific B-cells and stop autoantibody production. Remission rates of 82–100% have been reported.1–3 Rituximab is usually well tolerated; most relevant adverse events are infusion-related; less frequently, immunological disorders may occur, with a consequent increased risk of opportunistic infections. Pulmonary adverse reactions (5.3% of patients), described approximately 2 weeks after the last rituximab dose, are usually mild, transient, and steroid-responsive. Less frequent pulmonary complications include interstitial pneumonitis bronchiolitis obliterans, hypersensitivity pneumonitis and diffuse alveolar hemorrhage.4
Severe rituximab‐induced pneumonitis in an immunocompromised child with acquired thrombotic thrombocytopenic purpura / Testi, A.M., Moleti, M.L., Papoff, P., Paoletti, F., Trisolini, S., De Propris, M.S., Bianchi, S., Kaiser, F., Gentile, G.. - In: PEDIATRIC BLOOD & CANCER. - ISSN 1545-5009. - 69:2(2022). [10.1002/pbc.29375]
Severe rituximab‐induced pneumonitis in an immunocompromised child with acquired thrombotic thrombocytopenic purpura
Moleti, Maria Luisa;Papoff, Paola;Paoletti, Francesca;De Propris, Maria Stefania;Kaiser, Francesca;Gentile, Giuseppe
2022
Abstract
Immunosuppressive strategies with rituximab are increasing in patients with acquired thrombotic thrombocytopenic purpura (TTP) that is refractory/relapsing after standard treatment.1–3 Rituximab can effectively kill ADAMTS13-specific B-cells and stop autoantibody production. Remission rates of 82–100% have been reported.1–3 Rituximab is usually well tolerated; most relevant adverse events are infusion-related; less frequently, immunological disorders may occur, with a consequent increased risk of opportunistic infections. Pulmonary adverse reactions (5.3% of patients), described approximately 2 weeks after the last rituximab dose, are usually mild, transient, and steroid-responsive. Less frequent pulmonary complications include interstitial pneumonitis bronchiolitis obliterans, hypersensitivity pneumonitis and diffuse alveolar hemorrhage.4I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
